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Materials. Human CYP2J2 cDNA was obtained from OriGene (Catalog No. SC321730) and 
modified as published before1. Ampicillin, arabinose, chloramphenicol, isopropyl β-D-1-
thiogalactopyranoside (IPTG), and Ni-NTA resin were obtained from Gold Biotechnology. δ-
aminolevulinic acid was obtained from Frontier Scientific. NADPH and NADP+ were obtained 
from P212121.com. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-
hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-L serine (POPS) were purchased from 
Avanti Polar Lipids, Inc. AA, NADA, and NA5HT, SKF 525A (α-phenyl-α-propyl-
benzeneacetic acid, 2-(diethylamino)ethyl ester, monohydrochloride), AMG-9810 ((2E)-N-(2,3-
dihydro-1,4-benzodioxin-6-yl)-3-[4-(1,1-dimethylethyl)phenyl]-2-propenamide), capsaicin (N-
[(4-hydroxy-3-methoxyphenyl)methyl]-6E-8-methyl-nonenamide), and CP55940 (rac-5-(1,1-
dimethylheptyl)-2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol) were 
obtained from Cayman Chemical. AA for syntheses was obtained from NuChek. All other 
materials and reagents used were purchased from Sigma-Aldrich and Fisher Scientific. 
Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR). To measure IL-6, IL-
10, IL-1β, TNF-α, CYP2J9, CYP2J12, GAPDH, TRPV1, CB1, and CB2 mRNA, total RNA was isolated 
from BV2 microglial cells using the Direct-zol RNA Kit, according to the manufacturer’s instructions 
(Zymo Research). One microgram of RNA and random primers were used to synthesize the first strand of 
cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosciences). Total cDNA 
reaction samples were diluted 5-fold in RNAse/DNase-free water and were used as templates for 
amplification of each gene using the 7500 Real Time PCR System (Applied Biosciences). In addition, 
corresponding primers purchased from Integrated DNA Technologies (Supplementary Table 1) and the 
Power SYBR green PCR Master Mix (Applied Biosciences) were utilized during each qPCR reaction. 
The mRNA levels of IL-6, IL-10, IL-1β, TNF-α, CYP2J9, CYP2J12, TRPV1, CB1, and CB2 were 
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normalized to those of GAPDH, the internal control, and were analyzed using the 2-ΔΔCT method.2 Relative 
mRNA expression was calculated by taking the quotient of the treated sample (LPS + eVD) and 
LPS alone (IL-6, IL-10, IL-1β, and TNF-α mRNA) or the quotient of LPS-treated and LPS-
depleted samples (CYP2J9, CYP2J12, TRPV1, CB1, and CB2). Graphs show the relative mRNA 
expression of each sample for a given gene. The asterisks above each bar indicate the p-value 
associated with the standard deviation of each triplicate ΔCT value. P-values were calculated 
using a two-tailed t-test (α = 0.05): 0.0332 (*), 0.0021(**), 0.0002 (***), and < 0.0001 
(****).Primers used were designed as shown in Supplementary Table 1. 
BV2 Anti-inflammatory and Cytotoxicity Assays (Griess assay, IL-6 ELISA, and MTT). Assays 
were performed as previously described3. BV2 cells were seeded in 24-well plates (200,000 cells/mL) and 
grown to 80-90% confluency. For eVD screening and dose response studies, media was replaced with 
serum-free media and the cells were pre-incubated with eVDs for 4 hours prior to stimulation with 25 
ng/mL LPS (Sigma-Aldrich, USA). For epoxy-eVDs studies, BV2 were treated with the sEH inhibitor, t-
AUCB (1 µM), for 30 min prior to addition of epoxy-eVDs. For inhibition studies, CB1 antagonist, 
Rimonabant (1 µM), CB2 inverse agonist, AM630 (1 µM), TRPV1 antagonist, AMG 9810 (1 µM), were 
pre-incubated 30 min before addition of eVDs (1 µM) for 4 hrs. Media was collected after 24 hours and 
measured for NO levels (Griess assay) and IL-6 levels (ELISA) as previously described3. Cellular 
proliferation/cytotoxicity was assessed by testing the media with a commercially available MTT kit 
(Cayman Chemical Item No: #10009365).  
BrdU Cell Proliferation Assay. The BV-2 cells were seeded at 20,000 cells/0.1 mL in a 96-well plate. 
For eVD screening and dose response studies, media was replaced with serum-free media and the cells 
were pre-incubated with eVDs for 4 hours prior to stimulation with 25 ng/mL LPS for an additional 24 
hours (final well vol. 200 µL). For epoxygenated metabolites, serum-media was replaced with media 
containing 1 μM of sEH inhibitor (t-AUCB) for 30 min before adding epoVDs and LPS stimulation. 
6 
 
Briefly, after a 21 h incubation, BrdU (1x) was added to the plate for 3 hours. Next, the media was 
aspirated and the BV-2 cells were fixed according to manufacturer’s instruction (Millipore Sigma, Cat. 
No. 2750). BrdU incorporation was detected by the addition of anti-BrdU monoclonal antibody with Goat 
anti-mouse IgG peroxidase conjugate. Lastly, TMB substrate solution was added for 30 min at room 
temperature and stop solution was added. The positive wells were measured using a Biotek Synergy 2 
microplate reader (Biotek Instruments, Winooski, VT, USA) at an absorbance wavelength of 450 nm. 
Expression and purification of recombinant CYP2J2 in E. coli. Recombinant D34-CYP2J2 
containing a His5 tag was expressed and purified as previously performed
1,4. The D34-CYP2J2 is 
a 34-residue N-terminal truncation (residues 3-37) of CYP2J2 with a substitution of Leu2 for an 
Ala residue. These modifications have been previously shown to increase protein yield without 
affecting activity38, 45.  
Expression and purification of cytochrome P450 reductase. Expression of cytochrome 
P450 reductase (CPR) was performed as described previously1. 
Use of reactive oxygen species (ROS) scavengers. All in vitro metabolism data using 
recombinant proteins CYP2J2-CPR in nanodiscs were performed using ROS scavengers as 
previously described5. 
CYP2J2-mediated metabolism of NADA and NA5HT. Metabolism of NADA and NA5HT 
was performed in a lipid reconstituted system as previously described5,6. Briefly, 0.6 μM 
CYP2J2 and 0.6 μM CPR were incubated in a 20% POPS and 80% POPC reconstituted system 
in 0.5 mL of 0.1 M potassium phosphate buffer, pH 7.4 at 37o C with 100 μM NADA or NA5HT 
for 10 min. Reactions were initiated with 1 mM NADPH (final) and reacted for 60 min. 
Reactions were terminated by vortexing with 0.5 mL ethyl acetate. Adequate amount of NaCl(s) 
was added to facilitate layer separation. Metabolites were extracted thrice by vortexing the 
reactions for 1 min with 0.5 mL ethyl acetate followed by centrifugation at 1,984 x g at 4o C for 
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5 minutes to separate the layers. The organic layers were dried under a stream of N2(g) and 
resuspended in 0.1 mL of acetonitrile for HPLC and LC-MS/MS analysis. For all other 
experiments, CYP2J2 was incorporated into Nanodiscs. 
Incorporation of CYP2J2 into Nanodiscs.  Nanodiscs (NDs) containing CYP2J2 were 
prepared in 20% POPS and 80% POPC Nanodiscs as previously described7. NDs were used for 
all experiments using in vitro CYP2J2 except for initial product determination.  
Kinetics of NADA and NA5HT metabolism. The kinetics of NADA and NA5HT 
metabolism was determined using a CYP2J2- ND/CPR system as previous described7 with the 
following modifications. Reactions were performed with ROS scavengers as stated above. 
NADA and NA5HT (10-100 μM in DMSO) were incubated with CYP2J2-ND/CPR in 0.5 mL of 
0.1 M potassium phosphate buffer (pH 7.4) for 10 min. Reactions were initiated with the addition 
of 0.5 mM NADPH. The formation of epoxy-eVDs was determined to be linear up to 45 min, 
and so a 30-min reaction was utilized. Reactions were terminated upon the addition of 0.5 mL 
ethyl acetate and approximately 10 mg NaCl(s) to facilitate layer separation. The products were 
extract thrice with ethyl acetate, dried under a stream of N2(g), and resuspended in 180-proof 
ethanol for LC-MS/MS quantification. 
NADPH kinetics. The rate of NADPH oxidation by CYP2J2-ND/CPR was determined using 
UV-Vis spectroscopy as previously described8. The rate of the NADPH oxidation with CYP2J2-
ND/CPR without substrates was considered the “baseline” rate. 
AEA metabolism inhibition. AEA metabolism was determined as previously described6 with 
the following modifications. Reactions were performed in the presence of ROS scavengers as 
stated above and were terminated using 0.5 mL ethyl acetate and NaCl(s). 25 μM and 75 μM of 
NADA or NA5HT were used to inhibit AEA metabolism. 40 μM of AEA without inhibitor was 
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used as a control control to compare against our previous measurements for AEA metabolism6. 
The levels of AEA metabolism were similar to previously published and were used to assess 
saturation level (v/Vmax)
6.  EET-EAs and epoxy-eVDs were simultaneously quantified using LC-
MS/MS. 
Ebastine competitive binding. Relative binding affinities of eVDs binding to CYP2J2 were 
determined using an ebastine competitive binding assay as previously described.7  
LC-MS and LC-MS/MS analysis of CYP2J2 metabolites. CYP2J2 metabolism products 
were determined using HPLC Method 1. The Phenomenex column was used. LC-MS/MS 




Supplementary Note 1 
Previously, NADA was found in the cerebellum and hippocampus/thalamus regions in bovine 
and rat brains9-11, while NA5HT was identified in bovine brain extracts and in the intestine12,13. 
The levels of NADA and NA5HT have been reported to be <1-10 pmol ∙ g-1 in these brain 
tissues, which is lower than literature AEA levels (~20-80 pmol ∙ g-1)14 and lower than our 
reported levels for AEA in rat brains (150 pmol ∙ g-1) and pig brains (2800 pmol ∙ g-1)3. AEA 
levels are known to rise postmortem due to denaturation of the enzymes that degrade AEA15. 
Additionally, during tissue extraction, NADA and NA5HT are subjected to potential oxidation of 
the headgroups and their levels are expected to be lower than AEA. Of note, two separate 
extraction methods were used to detect eVDs and AEA (see methods). AEA was not well 
detected using the methanol/C-18 cartridges and the eVDs quickly degraded during the 
acetate:hexane extraction. Therefore, we cannot simultaneously quantify AEA and eVDs in the 
same sample. 
Supplementary Note 2 
Estimate of NA5HT binding at the second site 
We can definitively demonstrate that the eVDs bind to at least two sites in CYP2J2 from the 
kinetic curves; however, due to the solubility issues of the lipids, we cannot determine the kinetic 
parameters of their metabolism. Notwithstanding, we can obtain approximate values for the 
kinetic parameters of NA5HT based on a two-site binding equation using assumptions from 
other data (Equation 4). The assumptions are the following. (A) Negligible metabolism occurs at 
the unproductive site (𝐵1 = 0). (B) The EBS competitive binding and NADPH oxidation data 
represent the affinity at the first site and can be averaged to obtain 𝐾1 = 38 µM. (C) AEA 
potentiates the metabolism of 75 µM NA5HT by almost 100-fold with an apparent 𝑉max and 𝐾m 
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of 5.46 ± 1.91 nmol ∙ min-1 ∙ nmolCYP2J2-1 and 53.7 ± 35.7 μM, respectively. The apparent 𝑉max 
as AEA potentiates the metabolism of NA5HT may represent the 𝑉max of NA5HT metabolism 
(i.e., 𝐵2 = 5,460 pmol ∙ min
-1 ∙ nmolCYP2J2-1). Substituting these values into Equation 4, 𝐾2 is 
determined to be 5.36 ± 0.27 mM (Supplementary Figure 30). This demonstrates that the affinity 
of NA5HT for the second site is weak, which matches the observations of the data. There is not 
enough details in the NADA data to perform a similar analysis, but it is likely that NADA binds 








Supplementary Figure 1. 1H-NMR spectrum for NADA (400 Hz, CDCl3). Peak at 4.12 ppm 
corresponds to residual ethyl acetate. Other peaks for ethyl acetate overlap with NADA peaks 
































































Supplementary Figure 5. MS/MS spectra of synthesized (a) 14’,15’-epoNADA and (b) 
14’,15’-epoNA5HT standards along with fragmentation schemes. Data are obtained from LC-
MS/MS analysis. Fragment m/z values are given with deviation from the calculated m/z values 





Supplementary Figure 6. Effect of LPS in BV2 microglial cells on the relative mRNA 
expression of CYP2J12 and CYP2J9. BV2 microglial cells seeded at 200,000 cells/well in a 24-
well plate were treated with 100 ng/mL LPS for 3 hours. RT-qPCR detected the presence of 
CYP2J12 and CYP2J9 in BV2 cells. Data is from 3-pooled wells and is performed in technical 
replicates. Data is reported as the mean relative expression. Data can be found in the Source Data 
file. 





Supplementary Figure 7. Fragmentation scheme of (a) NADA, (b) acyl oxygenation of NADA 





Supplementary Figure 8. Mono-oxygenation of NADA by CYP2J2. (a) LC-MS/MS 
chromatogram in positive ion mode. Mass range is ± 5 ppm of the predicted product. (b-c) 








Supplementary Figure 9. Mono-oxygenation of NADA by CYP2J2. (a) LC-MS/MS 
chromatogram in negative ion mode. Mass range is ± 5 ppm of the predicted product. (b-i) 





Supplementary Figure 10. Di-oxygenation of NADA by CYP2J2. (a) LC-MS/MS chromatogram 
in negative ion mode. Mass range is ± 5 ppm of the predicted product. (b) MS/MS spectrum 





Supplementary Figure 11. Hydroxyquinonization of NADA by CYP2J2. (a) LC-MS/MS 
chromatogram in positive ion mode. Mass range is ± 6 ppm of the predicted product. (b) MS/MS 
spectrum of PD11. (c) Absorbance spectrum of PD11 obtained by UV-Vis HPLC analysis. 
NADA and cannabidiol hydroxyquinone (CBDHQ) were analyzed using a similar method and 
their absorbance spectra are given for comparison. It is known that dopamine is oxidized to form 






Supplementary Figure 12. Fragmentation scheme of (a) NA5HT, (b) acyl oxygenation of 
NA5HT (14’,15’-epoNA5HT shown as an example), and (c) Headgroup oxygenation of NA5HT 





Supplementary Figure 13. Mono-oxygenation of NA5HT by CYP2J2. (a) LC-MS/MS 
chromatogram in positive ion mode. Mass range is ± 5 ppm of the predicted product. (b-e) 





Supplementary Figure 14. Mono-oxygenation of NA5HT by CYP2J2. (a) LC-MS/MS 
chromatogram in negative ion mode. Mass range is ± 5 ppm of the predicted product. (b-c) 





Supplementary Figure 15. Di-oxygenation of NA5HT by CYP2J2. (a) LC-MS/MS 
chromatogram in positive ion mode. Mass range is ± 5 ppm of the predicted product. (b) MS/MS 





Supplementary Figure 16. Di-oxygenation of NA5HT by CYP2J2. (a) LC-MS/MS 
chromatogram in negative ion mode. Mass range is ± 5 ppm of the predicted product. (b) 





Supplementary Figure 17. Quinonization of NA5HT by CYP2J2. Quinonization was determined 
from the apparent oxygenation of the mono-oxygenation products (PS3 and PS4) indicated by a 
loss of 2 hydrogen atoms. (a) LC-MS/MS chromatogram in positive ion mode. Mass range is ± 5 





Supplementary Figure 18. Quinonization of NA5HT by CYP2J2. Quinonization was determined 
from the apparent oxygenation of the mono-oxygenation products (PS3 and PS4) indicated by a 
loss of 2 hydrogen atoms. (a) LC-MS/MS chromatogram in negative ion mode. Mass range is ± 










Supplementary Figure 20. LC-MS/MS analysis of capsaicin (CAP). (a) LC-MS/MS 
chromatogram in positive ion mode. Mass range is ± 5 ppm of the predicted product. (b) MS/MS 





Supplementary Figure 21. Demethylation of CAP by CYP2J2. (a) LC-MS/MS chromatogram in 





Supplementary Figure 22. Demethylation of CAP by CYP2J2. (a) LC-MS/MS chromatogram in 






Supplementary Figure 23. Mono-oxygenation of CAP by CYP2J2. (a) LC-MS/MS 
chromatogram in positive ion mode. Mass range is ± 5 ppm of the predicted product. (b) MS/MS 





Supplementary Figure 24. Mono-oxygenation of CAP by CYP2J2. (a) LC-MS/MS 
chromatogram in negative ion mode. Mass range is ± 5 ppm of the predicted product. (b-c) 





Supplementary Figure 25. Di-oxygenation of CAP by CYP2J2. (a) LC-MS/MS chromatogram 






Supplementary Figure 26. Hydroxyquinonization of CAP by CYP2J2. Hydroxyquinonization is 
determined by an oxidation of the demethylated CAP (PC1) indicated by the loss of two 
hydrogen atoms. (a) LC-MS/MS chromatogram in negative ion mode. Mass range is ± 5 ppm of 





Supplementary Figure 27. Biphasic NADPH oxidation in the presence of NA5HT. NADPH 
oxidation as CYP2J2-ND metabolizes NA5HT was determined by the absorbance of NADPH at 
340 nm. Data represents the SEM of three independent experiments. Representative spectra are 
shown. (a) NADPH oxidation rates with the indicated substrates. NA5HT shows biphasic 
NADPH oxidation kinetics. Phase I for all concentrations matches baseline rates (CPR and 
CYP2J2 without NA5HT). The Rates of Phase II are plotted in the figure. The 𝐾m and 𝑉max of 
Phase II are 27.3 ± 11.3 µM and 178 ± 28 nmolNADPH ∙ min-1 ∙ nmolCYP2J2-1, respectively. 
Ebastine (EBS) is monophasic and has kinetics parameters of 𝐾m = 18.9 ± 9.5 µM and 𝑉max = 
64.8 ± 12.1 nmolNADPH ∙ min-1 ∙ nmolCYP2J2-1. (b) Absorbance at 340 nm in the presence of the 
indicated amounts of NA5HT. Phase I rates are similar to those obtained with CPR and CYP2J2-
ND alone. Phase II shows a decrease in NADPH as a function of NA5HT concentration. (c) 
Experiments were repeated with NA5HT and CPR only. Rate of NADPH oxidation is similar to 
CPR alone. Adding CYP2J2-ND results in a rate of NADPH oxidation similar to the Phase II of 

















Supplementary Figure 28. 3D global fit of AEA inhibition by NADA as shown in Figure 3f. 
Rates are in pmolEET-EAs · min
-1 · nmolCYP2J2






Supplementary Figure 29. Regioselectivity of AEA epoxidation in the presence of eVDs. (a-c) 
Regioselectivity in the presence of NADA and (d-f) NA5HT at the indicated concentrations. 
Regioselectivity is shown as a percentage of the total EET-EAs. Control (Ctrl) refers to 40 µM 
AEA samples without eVDs, which was ran along with each experiment. Data in (c) and (f) 
show the dependence of the regioselectivity change on the concentrations of the eVDs as a 
function of an increasing ratio of the eVD:AEA. Degree of change is defined as the change in 
percentage value compared to control. Data from the 25 µM datasets are shown as dashed lines 
and the data from the 75 µM datasets are shown as solid lines. Data represents the mean ± SEM 
of 3 independent experiments. Statistical significance was determined by a two-tailed t-test with 
equal variance. *p < 0.05; **p < 0.01, ***p < 0.001. (g) Exact p values for the data. Yellow is p 








Supplementary Figure 30. NA5HT metabolism data fitted to a two-site (Equation 4) binding 
equation as detailed in the Results section. Data represents the mean ± SEM of 3 independent 







Supplementary Figure 31. MTT assay to determine cell viability. BV2 microglial cells seeded 
at 200,000 cells/well in a 24-well plate were treated with 25 ng/mL LPS for 24 hours and an 
MTT cell proliferation assay was performed to determine cell viability. Viability was determined 
as a percent of the formazan absorbance at 570 nm compared to LPS treatment only (100%) in 
the presence of (a) NA5HT, (b) 14’,15’-epoNA5HT, (c) NADA, and (d) 14’,15’-epoNADA. 

















Supplementary Figure 32. Effects of eVDS and epoxy-eVDs on cell proliferation. BV-2 
microglial cells were pre-incubated with varying concentrations of (a) NA5HT and 14,15-
epoNA5HT and (b) NADA and 14,15-epoNADA for 4 hours followed by LPS (25 ng/mL) 
stimulation for 24 hours. After 21 hours, BV-2 cell proliferation was measured using BrdU 
incorporation colorimetric ELISA assay. Values shown are the mean ± SEM of experiments 
performed in triplicate (n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001. (c) Tables for p-values 
of the data. Cells are highlighted as yellow p < 0.05, orange p < 0.01, and red p < 0.001. Data 






Supplementary Figure 33. Relative mRNA Expression of CB1, CB2, and TRPV1 in LPS-treated 
BV2 microglial cells. BV2 microglial cells seeded at 200,000 cells/well in a 24-well plate were 
treated with 25 ng/mL LPS for 24 hours. RT-qPCR detected the presence of TRPV1, CB1, and 
CB2 in BV2 cells. Data is from 3-pooled wells and is performed in technical replicates. Data is 
reported as the mean relative expression. Statistical analysis was performed using a two-tailed t-
test (α = 0.05). P-values: 0.0332 (*), 0.0021(**), 0.0002 (***), and < 0.0001 (****). Data can be 








Supplementary Figure 34. TRPV1 activation by vanilloids. Relative Ca2+ influx upon TRPV1 
activation was measured using a Fura-2 AM fluorescence assay. The fluorescence intensity at 
510 nm from the Ca2+-bound (excitation 340 nm) and Ca2+-free (excitation 380 nm) dye was 
measured over time at varying concentrations of ligands and are reported as a ratio (Fluorescence 
Ratio). Representative plots of (a) Capsaicin (CAP), (b) NADA, (c) 14’,15’-epoNADA, and (d) 
14’,15’-epoNA5HT from 4-6 separate experiments (2 sets of triplicate on separate days) are 






Supplementary Figure 35. TRPV1-mediated Ca2+ influx agonized by CAP and antagonized by 
AMG-9810. A Fura 2-AM fluorescence assay was used to determine TRPV1 binding in 
transfected HEK cells. 100% is defined as the Bmax of CAP binding. (a) CAP agonism data. (b) 
Antagonism of TRPV1 by AMG-9810. 250 nM of CAP was used to activate TRPV1. Data in (a-
b) is shown as the SEM of 4-6 experiments (2 sets of triplicate performed on separate days) and 
numbers above the data points represent the exact value of n. (c) HEK-TRPV1 cells were treated 
with 500 nM of reversible antagonist AMG-9810 30 min prior to stimulating with the indicated 
agonists. AMG-9810 prevented agonism of TRPV1 for all compounds. Data represents the SEM 
of 3 independent experiments. CAP was found to have an EC50 of 6.88 ± 3.36 nM, in accordance 



































Supplementary Figure 36. PRESTO-Tango assays of CB1 and CB2 activation. (a) Agonism of 
CB1. Data respresents the SEM of 3-6 separate experiments (2 sets of triplicates from separate 
days) Numbers above data points represent the exact value of n. (b) Agonism of CB2 by CP-
55940. Data represents the SEM of 3 independent experiments. (c) Co-administration of eVDs 
and CP-55940 to determine eVD binding to CB1 and 2. CB1 and CB2 were stimulated with 50 
nM of CP-55940 to determine antagonism by NADA (CB2), 14’,15’-epoNADA (CB2), 14’,15’-
epoNA5HT (CB2), and NA5HT (CB1). 100% is defined as the Bmax of CP-55940 binding. Data 
represents the SEM of 3 independent experiments. EC50 values for CP55940 were 0.91 ± 0.38 
nM and 5.2 ± 1.9 nM at CB1 and CB2, respectively and were similar to previously reported 
























Supplementary Table 1. Primers for Quantitative Polymerase Chain Reaction 
   





















































Supplementary Table 2. LC-MS/MS metabolite identification 




NADA Parent C28H41NO3 440.3159 55.4  
438.3014 
 -O C28H41NO4 456.3108 41.6; 42.6; 44.6; 




 -O2 C28H41NO5 472.3057 48.8 
53.0 
PD9 & PD10 
470.2912 
 -HQ C28H39NO4 454.2952 46.3 PD11 
452.2806 
NA5HT Parent C30H42N2O2 463.3319 55.6  
461.3174 




 -O2 C30H42N2O4 495.3217 50.5 PS5 
493.3072 
 -Q C30H40N2O3 477.3112 54.7 
56.8 
PS6 & PS7 
475.2969 




C17H25NO3 292.1907 36.7 PC1 
290.1762 
 -O C18H27NO4 322.2013 25.6 
26.6 
PC2 & PC3 
320.1867 
 -O2 C18H27NO5 338.1962 20.3 PC4 
336.1816 













ARG321 -8.92481 3.47937  
ARG495 -4.72929 1.37637  
ARG484 -3.76565 5.08937  
ASN185 -3.6608 0.91729  
LEU215 -3.13021 0.90826  
HIS494 -3.10337 2.63799  
HIS181 -2.99208 1.25837  
SER493 -2.98903 1.15341  
PRO491 -2.91059 2.22862  
TRP322 -2.7051 1.87051  
VAL492 -2.34359 0.69187  
LEU212 -2.29354 0.802  
THR313 -2.29139 0.656  
LEU481 -2.25677 2.00732  
LEU496 -1.88488 0.98401  
SER480 -1.76965 1.92706  
THR219 -1.65714 0.72366  
ASP216 -1.53383 0.59384  








ILE489 -3.25625 0.96471  
GLU222 -2.81904 7.20851  
THR114 -2.64145 1.26045  
ILE127 -2.4887 0.672  
THR488 -2.42929 1.62007  
PHE310 -2.33006 0.68078  
ASN231 -2.13378 1.40423  
ILE487 -2.12379 1.17521  
ARG117 -2.0808 1.03731  
MET400 -2.0443 0.97651  
ILE86 -1.86892 0.99568  
VAL380 -1.86384 0.53806  
ALA311 -1.75345 0.60574  
MET128 -1.71349 0.69304  




LEU83 -1.51171 0.79452  
GLN228 -1.16917 1.08287  
GLU314 -1.15822 0.47136  













ILE487 -5.89876 1.21444  
GLN228 -5.83744 2.55033  
GLY486 -4.4337 0.85385  
ILE489 -3.73012 1.80267  
THR488 -2.86717 1.23994  
LEU83 -2.66672 1.22142  
PRO381 -2.01531 0.5883  
MET400 -1.92187 0.59975  
ARG111 -1.86332 0.65592  
PHE61 -1.76106 0.70389  
PRO112 -1.56523 0.63967  
THR114 -1.38301 0.59581  
VAL380 -1.31937 0.42989  
LEU81 -1.29664 0.75077  
ILE86 -1.23497 0.69801  
ASN231 -1.23156 0.70985  
GLU82 -1.21236 0.75533  
ILE127 -0.93357 0.4817  








ASP307 -24.8669 9.39773  
PHE310 -5.45818 1.08501  
SER490 -4.84377 2.57133  
ILE489 -3.81991 1.27441  
ALA311 -2.55907 0.64457  
GLU222 -2.43978 6.04616  
THR315 -2.4274 0.79848  
GLU314 -1.99078 0.60895  
ILE127 -1.74117 0.56921  
VAL380 -1.56889 0.67457  
ILE376 -1.45199 0.64053  
ILE375 -1.40588 0.55081  
THR318 -1.24705 0.4895  
TRP251 -1.15856 0.49279  




THR219 -0.99602 0.86035  
PRO491 -0.87034 0.55172  
LEU126 -0.76823 0.67118  













ARG321 -21.757 3.21232  
TRP322 -4.69984 1.39869  
PRO491 -4.12342 1.47182  
ARG495 -3.77759 1.6088  
VAL492 -3.66875 0.78594  
SER493 -2.94951 0.78101  
ASN185 -2.82361 0.97184  
THR318 -2.74648 0.88867  
LEU215 -2.29793 0.59603  
LEU496 -2.1508 0.48536  
THR219 -1.81981 0.54936  
ASP216 -1.45737 0.6174  
THR313 -1.44611 0.63856  
HSD181 -1.23107 0.92312  
LEU212 -1.22474 0.5249  
SER317 -1.13683 0.42019  
SER480 -1.12392 0.50546  
SER490 -1.05437 0.5769  








GLU222 -5.78558 3.11688  
THR488 -3.52051 2.94825  
ILE489 -3.40178 1.07731  
VAL380 -3.0252 0.61197  
GLN228 -3.00795 2.10628  
ARG117 -2.86239 1.37033  
THR114 -2.8041 0.76497  
ARG111 -2.58118 0.899  
ILE127 -2.16936 0.67201  
ASN231 -1.96704 0.91609  
PRO112 -1.8457 0.72025  
PHE310 -1.78344 0.73298  
ALA311 -1.49405 0.50818  
PRO381 -1.43143 0.66267  




MET400 -1.26626 0.51045  
ILE487 -1.22545 1.01001  
THR315 -1.11141 0.64492  













GLN228 -6.5189 1.61495  
ILE487 -6.4654 1.07545  
GLY486 -5.05945 0.69118  
ASN231 -3.30921 1.13293  
THR488 -2.75129 0.70766  
MET400 -2.60969 0.64574  
LEU83 -2.51603 0.82828  
ILE86 -2.41382 0.70615  
ILE489 -2.06282 0.60377  
PHE61 -1.61387 0.53751  
GLU222 -1.59248 1.60739  
LEU81 -1.54611 0.58844  
SER490 -1.37099 0.95213  
GLU82 -1.32141 0.53585  
ALA88 -1.07485 0.34869  
MET485 -1.04278 0.39769  
ALA223 -1.02855 0.51492  
THR114 -1.0283 0.63714  








ARG117 -4.62722 1.01273  
PHE310 -4.25033 0.78785  
ILE489 -3.79065 0.7503  
PRO112 -3.53451 2.60917  
ILE127 -3.16155 0.66233  
VAL380 -3.0195 0.73603  
ARG111 -2.8175 0.86368  
ALA311 -2.54837 0.69605  
GLU314 -2.41186 0.5614  
THR315 -2.06731 0.79649  
THR114 -1.5682 0.61104  
ILE376 -1.48917 0.57733  
THR318 -1.26557 0.42192  
ILE375 -1.19388 0.4528  




VAL113 -0.87465 0.51344  
SER490 -0.83479 0.43952  
THR488 -0.62754 0.11655  






Supplementary Movie 1. Molecular dynamics (MD) simulations of NADA and AEA in 
Configuration 1. MD simulations were performed for 50 ns as described in the Methods section. 
In this configuration, AEA is bound in the PUFA binding pocket and NADA in the substrate 
access channel. Green spheres represent the 14’ and 15’ positions of NADA. 
 
Supplementary Movie 2. Molecular dynamics (MD) simulations of NADA and AEA in 
Configuration 2. MD simulations were performed for 50 ns as described in the Methods section. 
In this configuration, AEA is bound at the entrance of the substrate access channel and stabilizes 
the binding of NADA near the heme. Green spheres represent the 14’ and 15’ positions of 
NADA. 
 
Supplementary Movie 3. Molecular dynamics (MD) simulations of NA5HT and AEA in 
Configuration 1. MD simulations were performed for 50 ns as described in the Methods section. 
In this configuration, AEA is bound in the PUFA binding pocket and NA5HT in the substrate 
access channel. Green spheres represent the 14’ and 15’ positions of NA5HT. 
 
Supplementary Movie 4. Molecular dynamics (MD) simulations of NA5HT and AEA in 
Configuration 2. MD simulations were performed for 50 ns as described in the Methods section. 
In this configuration, AEA is bound at the entrance of the substrate access channel and stabilizes 
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